Abstract
Patients with multiple myeloma are known to have an increased risk of infections withStreptococcus pneumoniaeand vaccination is recommended. We retrospectively investigated the response of a 23‐valent polysaccharide‐based pneumococcal vaccine in 60 patients with multiple myeloma administered prior to autologous stem cell transplantation (ASCT). Specific antibody titers were measured before and after vaccination. Disease stage was evaluated and associated to the response. We found that 33% of the patients responded to the vaccine. There was a statistic significant association between response to the vaccine and disease stage (p = 0.01). We conclude that vaccination againstS. pneumoniaeprior toASCTis reasonable at least in patients responding well to induction therapy, but still it is important to be aware that the response is frequently poor and the duration of it is unknown.

This publication has 23 references indexed in Scilit: